By Lissette Talledo
Indian drugmaker Cipla has cut the generic version of Bayer’s Nevaxar by 75 percent. These are lung and brain cancer drugs which will be sold at 6,840 Rupees a month.
That is compared to how much Bayer sells these drugs for at 284, 428 per month.
Cipla says they do not expect these price cuts will affect their revenue. The products already have low volumes.
The reason for their decision is to make these drugs more affordable to patients.
Bayer is suing Cipla for patent infringement over Nexavar in court.
This occurred two months after India decided to allow another drugmaker to make a cheaper version of drugs despite Bayer’s objections.